Mithra Pharmaceuticals - Payment of the interests of the Highbridge/Whitebox loans Information on the total number of voting rights (denominator)
12 Mai 2023 - 5:45PM
Mithra Pharmaceuticals - Payment of the interests of the
Highbridge/Whitebox loans Information on the total number of voting
rights (denominator)
Payment of the interests of the
Highbridge/Whitebox loans Information on the total number of voting
rights (denominator)
Liege, Belgium,
12 May
2023 – 17:50 CET
– Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the
"Company" or "Mithra"), a company
dedicated to Women’s Health, today announces that, the third
quarterly interests of the loan facility concluded with funds
managed by Highbridge Capital Management, LLC
("Highbridge") and funds managed by Whitebox
Advisors, LLC ("Whitebox", and together with
Highbridge, each a “Lender”), was paid through
contribution in kind against the issuance of new shares for an
aggregate amount of EUR 641,289.61 through the issuance of 285,409
new shares at an issue price of EUR 2.25.
On 8th August 2022, the Company and the Lenders
entered into a three-year term senior secured convertible
facilities agreement for an amount of up to EUR 100 million, which
can be drawn in three tranches. The first tranche of EUR 50 million
was drawn upon signing of the agreement; the second tranche of EUR
25 million was drawn on 31st October 2022.
In accordance with article 15 of the Belgian Act
of 2 May 2007 on the disclosure of major participations in issuers
of which shares are admitted to trading on a regulated market and
regarding miscellaneous provisions, following this capital
increase’s completion Mithra now has 57,359,031 outstanding shares
carrying voting rights (against 57,073,622 outstanding shares
carrying voting rights previously).
Therefore, Mithra publishes the following
updated information:
- Capital: EUR
41,992,326.28
- Total number of
securities carrying voting rights: 57,359,031 (all ordinary
shares)
- Total number of
voting rights (= denominator): 57,359,031 (all relating to ordinary
shares)
- Number of
outstanding rights to subscribe to securities carrying voting
rights:
- Pursuant to the
share option plan of 5 November 2018: 1,394,900 subscription rights
giving right to 1,394,900 ordinary shares
- Pursuant to the
share option plan of 22 July 2020: 690,000 subscription rights
giving right to 720,571 ordinary shares
- Pursuant to the
share option plan granted to the lending shareholders of 7
September 2020: 300,000 subscription rights giving right to 313,292
ordinary shares
- Pursuant to the
share option plan of 20 November 2020: 390,717 subscription rights
giving rise to 390,717 ordinary shares
********
For more information, please
contact:
Investor relations
: investorrelations@mithra.com
About
Mithra
Mithra (Euronext: MITRA) is a Belgian biotech
company dedicated to transforming Women’s Health by offering new
choices through innovation, with a particular focus on
contraception and menopause. Mithra’s goal is to develop products
offering better efficacy, safety and convenience, meeting women’s
needs throughout their life span. Mithra explores the potential of
the unique native estrogen Estetrol in a wide range of applications
in women health and beyond. After having successfully launched the
first Estetrol-based product in 2021, the contraceptive pill
Estelle®, Mithra is now focusing on its second product Donesta®,
the next-generation hormone therapy. Mithra also offers partners a
complete spectrum of solutions from early drug development,
clinical batches and commercial manufacturing of complex polymeric
products (vaginal ring, implants) and complex liquid injectables
and biologicals (vials, pre-filled syringes or cartridges) at its
technological platform Mithra CDMO. Active in more than 100
countries around the world, Mithra has an approximate headcount of
230 staff members and is headquartered in Liège, Belgium.
www.mithra.com
ESTELLE®, and DONESTA® are registered trademarks
of Mithra Pharmaceuticals or one of its affiliates.
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
Subscribe to our mailing list on mithra.com to receive our press
releases by email or follow us on our social media :LinkedIn •
Twitter • Facebook |
-
2023-05-12_Mithra_Press-release_Coversion-Highbridge-Whitebox_FR -
Final
Mithra Pharmaceuticals (EU:MITRA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Mithra Pharmaceuticals (EU:MITRA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024